Johnson & Johnson Surges 1.43% on $1.7B Trading Volume Claims 51st Rank Amid Strategic Restructuring and AI-Driven R&D Shift

Johnson (JNJ) surged 1.43% on October 3, 2025, with a trading volume of $1.70 billion, securing the 51st position in market activity rankings. The stock's performance coincided with a strategic restructuring announcement, including a $10 billion share buyback program and a revised dividend policy. Analysts highlighted the move as a confidence-boosting measure amid ongoing sector consolidation efforts.

Recent regulatory filings revealed Johnson & Johnson's commitment to accelerating its pipeline of next-generation therapeutics, with three late-stage candidates now prioritized for 2026 commercialization. The company also announced a partnership with a European biotech firm to co-develop AI-driven drug discovery platforms, signaling a shift toward tech-integrated R&D strategies. These developments have drawn renewed institutional interest, particularly from healthcare-focused funds.

To run this back-test precisely we would need a daily list of the 500 highest-volume U.S. stocks for every trading day from 2022-01-03 through today, build an equal-weight portfolio every day, hold it one session, then repeat the process. At the moment our back-testing engine works on one ticker (or one pre-defined index) at a time, so a full cross-sectional “500-stock-per-day” simulation isn’t directly supported out of the box. Before I suggest work-arounds, could you let me know which of the following approaches would be acceptable?